Literature DB >> 14617009

Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas.

Davide Rossi1, Gianluca Gaidano, Annunziata Gloghini, Clara Deambrogi, Silvia Franceschetti, Eva Berra, Michaela Cerri, Chiara Vendramin, Annarita Conconi, Alessandra Viglio, Giuliana Muti, Pierluigi Oreste, Enrica Morra, Marco Paulli, Daniela Capello, Antonino Carbone.   

Abstract

Aberrant promoter hypermethylation is a mechanism of tumour suppressor gene inactivation. We explored aberrant promoter hypermethylation of multiple genes in 88 human immunodeficiency virus (HIV)-non Hodgkin lymphomas (NHL), 25 post-transplant lymphoproliferative disorders (PTLD) and five common variable immunodeficiency (CVI)-related NHL. Twenty-six of 79 (32.9%) HIV-NHL, eight of 14 (57.1%) PTLD and two of five (40.0%) CVI-NHL showed aberrant hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT). Aberrant hypermethylation of death-associated protein-kinase (DAP-K) occurred in 70 of 84 (83.3%) HIV-NHL, 19 of 25 (72.0%) PTLD and three of five (60.0%) CVI-NHL. These data implicate MGMT and DAP-K hypermethylation in lymphomagenesis of immunodeficient hosts. In particular, promoter hypermethylation of DAP-K represents the most frequent molecular alteration yet identified in immunodeficiency-related lymphomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617009     DOI: 10.1046/j.1365-2141.2003.04644.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 2.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

3.  Hodgkin lymphoma risk: role of genetic polymorphisms and gene-gene interactions in DNA repair pathways.

Authors:  Claudia M Monroy; Andrea C Cortes; Mirtha Lopez; Elizabeth Rourke; Carol J Etzel; Anas Younes; Sara S Strom; Randa El-Zein
Journal:  Mol Carcinog       Date:  2011-03-03       Impact factor: 4.784

Review 4.  Controversies in the treatment of Burkitt lymphoma in AIDS.

Authors:  Ariela Noy
Journal:  Curr Opin Oncol       Date:  2010-09       Impact factor: 3.645

Review 5.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 6.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

7.  Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.

Authors:  Kozue Ejima-Yamada; Yumi Oshiro; Seiichi Okamura; Tomoaki Fujisaki; Yasuhito Mihashi; Kazuo Tamura; Tomoko Fukushige; Masaru Kojima; Kazutoshi Shibuya; Morishige Takeshita
Journal:  Virchows Arch       Date:  2016-11-18       Impact factor: 4.064

8.  EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.

Authors:  Elizabeth L Courville; Sophia Yohe; David Chou; Valentina Nardi; Aleksandr Lazaryan; Beenu Thakral; Andrew C Nelson; Judith A Ferry; Aliyah R Sohani
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

9.  Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase.

Authors:  John Brognard; You-Wei Zhang; Lorena A Puto; Tony Hunter
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

Review 10.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.